Skip to main content
HCPCS J9232 · Level II · Part B drug

J9232: docetaxel, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9232

Billing unit
1 MG
Inj docetaxel (hospira) 1 mg
ASP payment limit
$0.513
October 2026; +0.2% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0977
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9232 is the Level II code for Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.513 per billing unit, up 0.2% from July 2026. Under OPPS it carries status indicator K in APC 0977. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names docetaxel: J9174 (Beizray from Zydus Pharmaceuticals (USA) Inc); J9172 (Docivyx from Avyxa Pharma, LLC); J9171 (the code whose CMS descriptor names no specific product). The ASP crosswalk maps 31 NDCs to it, sold as Docetaxel by Pfizer Inc, Sagent Pharmaceuticals, Baxter Healthcare Corporation. No current Billing and Coding Article lists J9232, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9232 at $0.513 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.512 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9232
QuarterPayment limitPerCoinsurance
October 2026$0.5131 MG20%
July 2026$0.5121 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 31 NDCs from 7 labelers to J9232. Report the NDC in the claim's drug segment and bill the number of J9232 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J9232
NDCDrug nameLabelerPackage sizeBilling units / package
00409-0016-01DocetaxelPfizer Inc16 × 1160
00409-0201-02DocetaxelPfizer Inc2 × 120
00409-0201-10DocetaxelPfizer Inc8 × 180
00409-0201-20DocetaxelPfizer Inc16 × 1160
00409-0365-01DocetaxelPfizer Inc8 × 1160
00409-0366-01DocetaxelPfizer Inc1 × 120
00409-0367-01DocetaxelPfizer Inc4 × 180
00409-0368-01DocetaxelPfizer Inc8 × 1160
00409-1732-01DocetaxelPfizer Inc16 × 1160
00409-2026-01DocetaxelPfizer Inc2 × 120
00409-4235-01DocetaxelPfizer Inc1 × 120
00409-5068-01DocetaxelPfizer Inc4 × 180
00409-7870-01DocetaxelPfizer Inc8 × 180
25021-0254-08DocetaxelSagent Pharmaceuticals8 × 180
25021-0254-16DocetaxelSagent Pharmaceuticals16 × 1160
43066-0001-01DocetaxelBaxter Healthcare Corporation2 × 120
43066-0006-01DocetaxelBaxter Healthcare Corporation8 × 180
43066-0010-01DocetaxelBaxter Healthcare Corporation16 × 1160
43066-0044-02DocetaxelBaxter Healthcare Corporation2 × 120
62332-0678-02DocetaxelAlembic Pharmaceuticals Inc.2 × 120
62332-0678-08DocetaxelAlembic Pharmaceuticals Inc.8 × 180
62332-0678-16DocetaxelAlembic Pharmaceuticals Inc.16 × 1160
66758-0050-01DocetaxelSandoz Inc.2 × 120
66758-0050-02DocetaxelSandoz Inc.8 × 180
66758-0050-03DocetaxelSandoz Inc.16 × 1160
67457-0531-02DocetaxelMylan Institutional LLC2 × 120
67457-0532-08DocetaxelMylan Institutional LLC8 × 180
67457-0533-16DocetaxelMylan Institutional LLC16 × 1160
71288-0144-08DocetaxelMeitheal Pharmaceuticals Inc.8 × 180
71288-0144-16DocetaxelMeitheal Pharmaceuticals Inc.16 × 1160
72078-0040-08DocetaxelMylan Institutional LLC8 × 180

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J9232 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for J9232 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9232 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9232 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9232 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9232 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9232 carries status indicator K and is assigned to APC 0977, with a published national unadjusted payment of $0.51. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9232 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $0.51 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J9232 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9232

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9232

What does HCPCS code J9232 describe?

J9232 is defined by CMS as "Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9232 a CPT code?

No. J9232 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as docetaxel; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9232 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9232 in October 2026?

The ASP-based payment limit is $0.513 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.512. Commercial payers use their own fee schedules.

Which NDCs map to J9232?

The October 2026 ASP crosswalk lists 31 NDCs from 7 labelers: Docetaxel (Pfizer Inc); Docetaxel (Sagent Pharmaceuticals); Docetaxel (Baxter Healthcare Corporation); Docetaxel (Alembic Pharmaceuticals Inc.). For example NDC 00409-0016-01 (package size 16) equals 160 billing units of J9232.

Does J9232 have NCCI bundling edits?

No active practitioner PTP pairs list J9232 as a column-1 or column-2 code in the v323r0 release.

J9232 vs J9174: what is the difference?

Both are HCPCS Level II codes whose descriptor names docetaxel. What sets J9174 apart: Beizray from Zydus Pharmaceuticals (USA) Inc. J9232 is billed per 1 mg, limit $0.513; J9174 is billed per 1 mg, limit $46.531, MUE 320. Report the code whose descriptor matches the product and setting in the record.

J9232 vs J9172: what is the difference?

Both are HCPCS Level II codes whose descriptor names docetaxel. What sets J9172 apart: Docivyx from Avyxa Pharma, LLC. J9232 is billed per 1 mg, limit $0.513; J9172 is billed per 1 mg, limit $46.193, MUE 300. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.